Non-Drug Costs Associated with Outpatient Infliximab Administration in Pediatric Inflammatory Bowel Disease

Abstract

Non-drug costs represent a substantial proportion of the total cost of outpatient infliximab-related actual costs in inflammatory bowel disease. Personnel costs represent the largest segment of the non-drug costs. The actual drug costs of infliximab represent a small proportion of the total costs.